Trial Profile
Single and Multiple Dose -Based Tolerability, Safety and Pharmacokinetic Phase 1 Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Patients With Psoriasis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Itolizumab (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Biotech Pharmaceutical
- 26 Apr 2023 Status changed from recruiting to discontinued.
- 11 Jan 2016 New trial record